Ecomike Tuesday, 09/29/20 02:17:05 PM Re: ChaseDog31 post# 17073 Post # of 17919 Just to be clear, My comment was that this guys "Cutting edge nano Tech" is next generation Nano tech built on Fountains tech that goes back 40 years. Fountain is a 10% founding shareholder of the firm that R/M to form NDTP. Fountain, Dr. Fountain was a co-founder of the Liposome company some 40 years ago, that held many of his patents. It sold for close to a Billion dollars 20 years ago. 13 and 10 years ago Fountain was spear heading the #TBI Traumatic Brain Injury, Nano-Liposome delivery tech of Nutrients to the brain at the Univ of So. Florida. 7 years ago Fountain, Mathias, Kubin, Hovis and Yarbrough started CCA, LLC up with a JV R&D effort at the Univ of Penn Hospital where the 2007/2010 Fountain work was moved from the lab to some Human trials in 2013 and 2016, 2018..... That I have the R&D papers on. Now we also have the latest cutting edge work by Professor Mark Kester on board. The Point is the Nano Liposome tech of today, Mark Kester, $NDTP, is built on top of 1-40 year old Dr. Fountain foundational work. Hovis is the perfect CEO/seasoned attorney guy for licensing to drug companies, because that is what he does. After all he made and kept the 2013 to 2020 UPennMed JV deal alive and well for 7 years. No doubt he may hire or farm out key work, and oversee it, and also do any licensing of drink line deal with say PepsiCo. When the time comes, I am sure Hovis may hire a CEO while the big dogs, including him run the BOD-of-$NDTP "Stay tuned. This could get really interesting really fast. " Good news is we have our own hard core DD Science, Nano-tech team, that knows and understands what NDTP is, and has and is doing. But yes, this is not going to be a one trick pony. All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.